Brought to you by 
AbbVie, BMS to test Rova-T, Opdivo, and Opdivo + Yervoy combinations; terminated
07 Oct 2021
Executive Summary
AbbVie Inc. announced it would test combinations of its Rova-T (rovalpituzumab tesirine) with Bristol-Myers Squibb Co.'s Opdivo (nivolumab) and Opdivo and Yervoy (ipilimumab) combination.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Gene Therapy, Cell Therapy
- Immuno-Oncology
-
Large Molecule
- Antibodies
Deal Status
- Terminated
Deal Type
-
Alliance
- Trial Collaborations
- R&D (No Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
AbbVie, BMS to test Rova-T, Opdivo, and Opdivo + Yervoy combinations; terminated
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice